Cargando…

Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes

INTRODUCTION: Osteomyelitis is a difficult-to-cure infection, with high relapse rate despite adequate therapy. Large published osteomyelitis series in adults are rare. MATERIAL AND METHODS: A total of 344 adult osteomyelitis patients were studied and followed > 12 months after hospital discharge....

Descripción completa

Detalles Bibliográficos
Autores principales: del Pozo, Elena García, Collazos, Julio, Cartón, José Antonio, Camporro, Daniel, Asensi, Víctor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166254/
https://www.ncbi.nlm.nih.gov/pubmed/29756429
_version_ 1783360002039218176
author del Pozo, Elena García
Collazos, Julio
Cartón, José Antonio
Camporro, Daniel
Asensi, Víctor
author_facet del Pozo, Elena García
Collazos, Julio
Cartón, José Antonio
Camporro, Daniel
Asensi, Víctor
author_sort del Pozo, Elena García
collection PubMed
description INTRODUCTION: Osteomyelitis is a difficult-to-cure infection, with high relapse rate despite adequate therapy. Large published osteomyelitis series in adults are rare. MATERIAL AND METHODS: A total of 344 adult osteomyelitis patients were studied and followed > 12 months after hospital discharge. Demographic, microbiological, clinical, therapeutic and outcome data were analyzed. RESULTS: Mean age was 52.5 ± 18.3 years and 233 (67.7%) were male. Main osteomyelitis types were post-surgical (31.1%), post-traumatic (26.2%) and hematogenous (23%). Tibia (24.1%) and femur (21.8%), and methicillin-susceptible S. aureus (29.6%) were the most commonly involved bone and bacteria, respectively. Median follow-up was 12.0 (IQR 0-48) months. Inflammatory markers were increased in 73.6%. Overall, patients were treated by IV and oral routes with one (IV: 44.5%, oral: 26.7%), two (IV: 30.1%, oral: 21.8%) or ≥ 2 (IV: 15.2%, oral: 6.1%) antibiotics. Median duration on IV/oral antimicrobials was 28.0 (IQR 24-28) and 19.5 (IQR 4-56) days, respectively. Anti-staphylococcal β-lactams cloxacillin/cefazolin (19.2%) and ciprofloxacin (5.5%) were the most frequently used IV and orally, respectively. Overall 234 (68.0%) underwent surgery, 113 (32.8%) debridement, 97 (27.4%) debridement + muscle flap and 24 (7%) amputation. At the end of follow-up 208 patients (60.6%) did not have relapsed. Operated patients had significantly less relapses (p<0.0001). A total of 23 (6.7%) died, 11 (3.2%) by infectious complications and 48 (14%) were lost in the follow-up. CONCLUSIONS: Osteomyelitis is due to different causes complicating its therapy. Risk factors or causal microorganism could influence its treatment and outcome. Aggressive surgery along with adequate antimicrobial therapy are mandatory for cure.
format Online
Article
Text
id pubmed-6166254
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-61662542018-10-03 Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes del Pozo, Elena García Collazos, Julio Cartón, José Antonio Camporro, Daniel Asensi, Víctor Rev Esp Quimioter Original INTRODUCTION: Osteomyelitis is a difficult-to-cure infection, with high relapse rate despite adequate therapy. Large published osteomyelitis series in adults are rare. MATERIAL AND METHODS: A total of 344 adult osteomyelitis patients were studied and followed > 12 months after hospital discharge. Demographic, microbiological, clinical, therapeutic and outcome data were analyzed. RESULTS: Mean age was 52.5 ± 18.3 years and 233 (67.7%) were male. Main osteomyelitis types were post-surgical (31.1%), post-traumatic (26.2%) and hematogenous (23%). Tibia (24.1%) and femur (21.8%), and methicillin-susceptible S. aureus (29.6%) were the most commonly involved bone and bacteria, respectively. Median follow-up was 12.0 (IQR 0-48) months. Inflammatory markers were increased in 73.6%. Overall, patients were treated by IV and oral routes with one (IV: 44.5%, oral: 26.7%), two (IV: 30.1%, oral: 21.8%) or ≥ 2 (IV: 15.2%, oral: 6.1%) antibiotics. Median duration on IV/oral antimicrobials was 28.0 (IQR 24-28) and 19.5 (IQR 4-56) days, respectively. Anti-staphylococcal β-lactams cloxacillin/cefazolin (19.2%) and ciprofloxacin (5.5%) were the most frequently used IV and orally, respectively. Overall 234 (68.0%) underwent surgery, 113 (32.8%) debridement, 97 (27.4%) debridement + muscle flap and 24 (7%) amputation. At the end of follow-up 208 patients (60.6%) did not have relapsed. Operated patients had significantly less relapses (p<0.0001). A total of 23 (6.7%) died, 11 (3.2%) by infectious complications and 48 (14%) were lost in the follow-up. CONCLUSIONS: Osteomyelitis is due to different causes complicating its therapy. Risk factors or causal microorganism could influence its treatment and outcome. Aggressive surgery along with adequate antimicrobial therapy are mandatory for cure. Sociedad Española de Quimioterapia 2018-07-12 2018-06 /pmc/articles/PMC6166254/ /pubmed/29756429 Text en © The Author 2018 https://creativecommons.org/licenses/by-nc/4.0/ The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original
del Pozo, Elena García
Collazos, Julio
Cartón, José Antonio
Camporro, Daniel
Asensi, Víctor
Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title_full Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title_fullStr Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title_full_unstemmed Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title_short Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
title_sort bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166254/
https://www.ncbi.nlm.nih.gov/pubmed/29756429
work_keys_str_mv AT delpozoelenagarcia bacterialosteomyelitismicrobiologicalclinicaltherapeuticandevolutivecharacteristicsof344episodes
AT collazosjulio bacterialosteomyelitismicrobiologicalclinicaltherapeuticandevolutivecharacteristicsof344episodes
AT cartonjoseantonio bacterialosteomyelitismicrobiologicalclinicaltherapeuticandevolutivecharacteristicsof344episodes
AT camporrodaniel bacterialosteomyelitismicrobiologicalclinicaltherapeuticandevolutivecharacteristicsof344episodes
AT asensivictor bacterialosteomyelitismicrobiologicalclinicaltherapeuticandevolutivecharacteristicsof344episodes